Reprint

Cell Therapy, Bispecific Antibodies and other Immunotherapies Against Cancer

Edited by
November 2023
194 pages
  • ISBN978-3-0365-9566-5 (Hardback)
  • ISBN978-3-0365-9567-2 (PDF)

This book is a reprint of the Special Issue Cell Therapy, Bispecific Antibodies and other Immunotherapies Against Cancer that was published in

Biology & Life Sciences
Medicine & Pharmacology
Summary

This Special Issue in Cancers is focused on cell therapy, bispecific antibodies, and other immunotherapies against cancer. It includes reports on cell therapies such as CAR-NK cell therapies, and bispecific antibodies against multiple myeloma and B cell lymphoma. Immunotherapies against solid tumors include TGF-beta-PDL-1 fusion protein and EpCAM-CD3 bispecific antibody generated with mRNA-lipid nanoparticles (LNP) against colorectal tumors. The clinical studies ongoing with bi- and tri-specific T cell engager antibodies against solid tumors and advantages versus cell therapies are discussed. This Special Issue highlights novel approaches to cell therapies, bispecific antibodies, vaccines, and immunotherapies that will be interesting for cancer cell researchers, biologists, and oncologists.

Format
  • Hardback
License
© by the authors
Keywords
CAR T-cell therapy; glofitamab; diffuse large B-cell lymphoma (DLBCL); relapse; multiple myeloma; BCMA; bispecific antibody; CAR-T-cell therapy; mRNA COVID-19 vaccines; humoral antibody responses; diffuse large B-cell lymphoma (DLBCL); bispecific antibodies; lymphoma; autoimmune diseases; apoptosis; CD20; CD19; CD95; cancer immunotherapy; PD-L1; TGF-β; bifunctional fusion protein; BR102; chimeric antigen receptors; CAR-NK; CAR-T; metastatic melanoma; uveal melanoma; patient-derived xenograft mouse model; adoptive T cell therapy; chimeric antigen receptor T cells; immunotherapy; canine; companion dog; comparative oncology; HER2; NK cell; cancer immune cell therapy; checkpoint blockade immunotherapy; lung cancer; TIGIT blockade; bi-/trispecific antibodies; T-cell engagers; solid tumors; colorectal cancer; EpCAM; CD3; bispecific antibody; immunotherapy; cell–cell interaction; intercellular labeling; intercellular imaging; bioinformatics; cancer; n/a